ArticleOncotarget2015

ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.

Anke Bill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.